Results 61 to 70 of about 12,657,081 (210)
British Journal of Clinical Pharmacology, EarlyView.Aims This study aimed to evaluate the safety, tolerability and pharmacokinetics of a novel oral modified‐release psilocybin formulation (REL‐P11) in normal‐weight and overweight/obese healthy adults and to assess its suitability for controlled, subperceptual exposure, in light of emerging evidence supporting serotonergic modulation in metabolic ...
Anna Signor +11 more
wiley +1 more source
Hepatitis B vaccine : what you need to know [PDF]
Hepatitis B is a serious disease that affects the liver. It is caused by the hepatitis B virus. Hepatitis B can cause mild illness lasting a few weeks, or it can lead to a serious, lifelong illness.Hepatitis B virus infection can be either acute or ...
core +6 more sources
Adverse event reporting following immunization of hepatitis B vaccine: A 13-year review
Human Vaccines & ImmunotherapeuticsHepatitis B vaccination is the most effective means of interrupting HBV transmission. Although the hepatitis B vaccine is very effective and safe, adverse events following immunization do occur and need to be reported so that problems can be identified ...
Xiaoying Gong +4 more
doaj +1 more source
A Pre-Clinical Safety Evaluation of SBP (HBsAg-Binding Protein) Adjuvant for Hepatitis B Vaccine. [PDF]
PLoS ONE, 2017 Although adjuvants are a common component of many vaccines, there are few adjuvants licensed for use in humans due to concerns about their toxic effects.
Jingbo Wang +6 more
doaj +1 more source
Biotechnology and Bioengineering, EarlyView.ABSTRACT Virus‐like particles (VLPs) are a promising modality with extensive applications in prophylactic and therapeutic vaccine design. Human Papillomavirus (HPV) vaccines are one such example where VLP vaccine applications have led to the successful reduction in HPV‐associated diseases, such as cervical cancer.
Nicholas Samuelson +5 more
wiley +1 more source
Viral Hepatitis Journal, 2012 Hepatitis B virüs (HBV) infection is a disease which can be prevented by vaccination. Nowadays many effective and safe vaccines have been developed. Although HBV vaccinations are begun in 1982 in the world, the vaccination rates cannot reach to adequate ...
Selma TOSUN
doaj +1 more source
Bridging the translational gap in clinical nanomedicine: From rational design to clinical reality
BMEMat, EarlyView.Nanotechnology offers a multi‐faceted approach to modern healthcare, encompassing high‐sensitivity diagnostic imaging, innovative vaccine delivery, and targeted therapeutics. This review explores how these nanomedicine applications address critical challenges in cancer recurrence and the treatment of neurologic and respiratory diseases to combat rising
Ahmed H. Ghonaim +9 more
wiley +1 more source
Hepatitis B Vaccine: Four Decades on
VaccinesHepatitis B virus is a substantial contributor to cirrhosis and hepatocellular carcinoma (HCC) globally. Vaccination is the most effective method for prevention of hepatitis B and its associated morbidity and mortality, and the only method to prevent ...
Maria Mironova, Marc G. Ghany
doaj +1 more source
Journal of Public Health in Africa, 2016 More than two billion people have been infected with hepatitis B virus (HBV), 360 million have chronic infection and 600,000 die each year from HBV-related liver disease or hepatocellular carcinoma.
Berhanu Elfu Feleke
doaj +1 more source